Date:	11/28/2023
Your Name:	Elena Tsoy
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None         Alzheimer's Association         NIH/NIA         NIH/NIA         NIH/NIDS         Global Brain Health Institute	AARF-21-851552 P30AG062422 R35AG072362 U01NS128913
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	Nih/NiA	R21AG080410
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None     American Psychological Association	August 2023, payment made to me
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	<ul> <li>None</li> <li>The Aga Khan University, Nairobi, Kenya</li> <li>Washington University in St Louis, St Louis, MO</li> </ul>	November 2023, travel support October 2023, travel and lodging support
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☑ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/21/2023
Your Name:	Renaud La Joie
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		
		Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH/NIA       NIH/NIA	P30AG062422 R35AG072362	
		Time frame: past 36 months	5	
2	Grants or contracts from any entity (if not indicated in item #1 above).	<ul> <li>None</li> <li>NIH/NIA</li> <li>US Department of Defense</li> <li>Alzheimer's Association Research Grant</li> </ul>	Paid to my institution Paid to my institution AARG-22-926899; paid to my institution	
3	Royalties or licenses	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None   University of Pennsylvania	honoraria for lecture; paid to me directly
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☑ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/28/2023
Your Name:	Lawren VandeVrede
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH/NIA Alzheimer's Association Clinician Scientist Fellowship Shenandoah Foundation Time frame: past 36 mont	K23AG073514         Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	☑ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None      Retrotope	Payment made to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None     PSP Sleep Trial	Data Safety Monitoring Board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/28/2023
Your Name:	Julio C Rojas
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g.,	NIH/NIA	K23AG059888
	funding, provision of study materials,		
	medical writing,		Click the tab key to add additional rows.
	article processing		
	charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 months	
2	Grants or	□ None	
	contracts from any entity (if not indicated in item	Site PI for clinical trials sponsored by Eli Lilly	Paid to institution.
		Site PI for clinical trials sponsored by Elizari	Paid to institution.
	#1 above).		
3	Royalties or	⊠ None	
	licenses		

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	ents were
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑       None         □       □         □       □         □       □         □       □	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	☑       None         □       □         □       □         □       □         □       □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑         None           □         □           □         □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/27/2023
Your Name:	Claire Yballa
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	ents were
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑         None	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	☑       None         □       □         □       □         □       □         □       □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	✓       None         —       —         —       —         —       —         —       —         —       —         —       —         —       —	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:         I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/22/2023
Your Name:	Brandon Chan
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	s were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:         I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/28/2023
Your Name:	Argentina Lario Lago
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None	Click the tab key to add additional rows.
		1	Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses		None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	ents were
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑         None	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	☑       None         □       □         □       □         □       □         □       □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	✓       None         —       —         —       —         —       —         —       —         —       —         —       —         —       —	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:         I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/27/2023
Your Name:	Anne-Marie Rodriguez
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	s were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:         I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/27/2023
Your Name:	Collette A Goode
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	s were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:         I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/27/2023
Your Name:	Sabrina J Erlhoff
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	s were
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	12/4/2023
Your Name:	Boon Lead Tee
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None         National Institute of Aging (R21AG068757, R01AG080469, P30AG062422, R01AG083840)         Alzheimer's Association (AACSFD-22-97214)	Support salary for me and indirect cost for UCSF Support salary for me and indirect cost for UCSF Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None           Global Brain Health Institute/UCSF (PHHE-GBHI-7030526)	Support salary for me
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	<ul> <li>None</li> <li>National Institute of Aging</li> <li>Alzheimer's Association</li> </ul>	Support for travel Support for travel
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☑ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	12/4/2023
Your Name:	Charles Windon
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Nih/NiA       Nih/NiA	P30AG062422         R35AG072362         Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None     Alzheimer's Association	AACSFD-21-872476
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     LCN Consulting     The Kinetix Group	Payment to Me Payment to Me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None     American Academy of Neurology	Payment to me
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑         None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☑ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/29/2023
Your Name:	Serggio Lanata
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g.,	□ None	P30AG062422
	funding, provision of study materials, medical writing, article processing		Click the tab key to add additional rows.
	charges, etc.) No time limit for this item.		
		Time frame: past 36 months	
2	Grants or contracts from	□ None	
	any entity (if not	,	RF1AG032289
	indicated in item	NIH/NIA	R01AG070883
	#1 above).		
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None     Expert neurologist for medicolegal case	I have not been paid yet
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	☑ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☑ None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/29/2023
Your Name:	Joel H Kramer
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None       NIH/NIA       NIH/NIA	P30AG062422         R35AG072362         Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	☑ None	
3	Royalties or licenses	None   Pearson [California Verbal Learning Test]	Payment made to me

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	ents were
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑       None         □       □         □       □         □       □         □       □	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	☑       None         □       □         □       □         □       □         □       □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑         None           □         □           □         □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/28/2023
Your Name:	Bruce L Miller
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	□ None NIH/NIA NIH/NIA	P30AG062422 R35AG072362 Click the tab key to add additional rows.
r a c N	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	NiH/Univ. of Wisconsin, Madison         Bluefield Project to Cure FTD, UCSF FTD Core         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA         NIH/NIA	1R01AG070883 P0544014 P01AG019724 R01AG057234 R01AG062562 R01AG062588 R01AG052496

		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were
		relationship or indicate none (add rows as needed)	made to you or to your institution)
		· · · ·	,,
3	Royalties or	□ None	
	licenses		[]
		Cambridge University Press	Payment made to me
		Elsevier, Inc.	Payment made to me
		Guilford Publications, Inc.	Payment made to me
		Johns Hopkins Press	Payment made to me
		Oxford University Press	Payment made to me
		Taylor & Francis Group	Payment made to me
4	Consulting fees	□ None	
		Massachusetts General Hospital Alzheimer's	Payments made to me in 2021, 2022, and 2023
		Disease Research Center (ADRC) Scientific	
		Advisory Board (SAB)	
		Stanford University ADRC SAB	Payments made to me in 2021, 2022, and 2023
		University of Washington ADRC SAB	Payments made to me in 2021, 2022, and 2023
		Genworth Medical Advisory Board	Payment made to me in Mar 2023
5	Payment or	□ None	
	honoraria for		
	lectures,	Fromm Institute for Lifelong Learning	May 2023, payment made to me
	presentations,	Global Summit on Neurodegenerative Diseases	Jun 2021, payment made to me
	speakers	Korean Dementia Society	Jul 2022, payment made to me
	bureaus,	Massachusetts General Hospital, dementia course	Payments made to me in 2022 and 2023
	manuscript	National MS Society, Don Paty Lectureship	Jun 2021, payment made to me
	writing or	Ochsner Neuroscience Institute	Nov 2021, payment made to me
	educational	Providence Saint Joseph Medical Center	Sep 2021, payment made to me
	events	Taipei Medical University, Dementia Center	Mar 2022, payment made to me
		UC Irvine Institute for Memory Impairments and	Mar 2022, payment made to me
		Neurological Disorders (UCI MIND)	
		University of California, Los Angeles (UCLA) Grand	Apr 2022, payment made to me
		Rounds	
		University of Texas, Center for Brain Health	Jan 2021, payment made to me
6	Payment for expert testimony	⊠ None	
7	Support for attending	□ None	
	meetings and/or travel	The Association for Frontotemporal Degeneration (AFTD) Education Symposium, St. Louis, MO	May 2023, travel and lodging support
		Milken Institute FTD Scientific Retreat, Los Angeles, CA	Mar 2023, travel and lodging support
		California Institute of the Arts, Los Angeles, CA	Apr 2022, travel and lodging support
		UCLA	Apr 2022, travel and lodging support

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	☑         None	
9	Participation on a Data Safety	□ None	
	Monitoring	Arizona Alzheimer's Consortium	External Advisor
	Board or	Association for Frontotemporal Degeneration	Scientific Advisor
	Advisory Board	The Buck Institute for Research on Aging	Scientific Advisor
		Cure ALS	Scientific Advisor
		The John Douglas French Alzheimer's Foundation	Medical Advisor
		Fundación Centro de Investigación Enfermedades Neurológicas, Madrid, Spain	Scientific Advisor
		Genworth	Scientific Advisor
		Kissick Family Foundation	Scientific Advisor
		The Larry L. Hillblom Foundation	Scientific Advisor
		Massachusetts General Hospital ADRC	Scientific Advisor
		National Institute for Health Research Cambridge Biomedical Research Center and its subunit, the	Scientific Advisor
		Biomedical Research Unit in Dementia	
		Stanford University ADRC	Scientific Advisor
		University of Southern California P01 Urban Air Pollution and Alzheimer's Disease: Risk, Heterogeneity, and Mechanisms	External Advisory Committee
		University of Washington ADRC	Scientific Advisor
<b>10</b> Leadership or fiduciary role in		□ None	
	other board,	The Bluefield Project to Cure FTD	Director and Internal Advisor
	society,	Global Brain Health Institute	Founding Director
	committee or	Institute for Neurodegenerative Diseases	Affiliated Faculty
	advocacy group,	Tau Consortium of the Rainwater Charitable Fdtn.	Co-Director and Scientific Advisor
	paid or unpaid		
11	Stock or stock options	⊠ None	
12	Receipt of equipment,	⊠ None	
	materials, drugs, medical writing,		
	gifts or other services		

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	12/6/2021
Your Name:	Peggye Dilworth-Anderson, PhD
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for</b>	NIH	None /NIA	R35AG072362 Click the tab key to add additional rows.
	this item.			
2	Grants or contracts from any entity (if not indicated in item #1 above).		Time frame: past 36 month None	
3	Royalties or licenses		None	

		Name all entities with whom you have thisSpecifications/Comments (e.g., if paymentsrelationship or indicate none (add rows as needed)made to you or to your institution)	ents were
4	Consulting fees	☑     None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	☑       None         □       □         □       □         □       □         □       □	
7	Support for attending meetings and/or travel	☑       None         □       □         □       □         □       □         □       □	
8	Patents planned, issued or pending	☑       None         □       □         □       □         □       □         □       □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑         None           □         □           □         □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea ×	Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/30/2023
Your Name:	Adam L Boxer
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	<ul> <li>None</li> <li>NIH, Bluefield Project, Rainwater Charitable</li> <li>Foundation, GHR Foundation, AFTD, Alzheimer's</li> <li>Association</li> <li>Biogen, Eisai, Regeneron</li> </ul>	
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Alector, Arrowhead, Arkuda, Arvinas, Amylyx, Aviado, Eli Lilly, Merck, Roche, UnlearnAl, Modalis, Oligomerix, Oscotec, Roche, Transposon	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	☑     None	
8	Patents planned, issued or pending	☑     None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☑     None	

			ifications/Comments (e.g., if payments were e to you or to your institution)
11	Stock or stock options	None       Alector, Arvinas, Arkuda	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	☑         None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	12/4/2023
Your Name:	Gil D Rabinovici
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present		
	manuscript (e.g.,	NIH/NIA P30AG062422	Paid to institution
	funding, provision	NIH/NIA R35AG072362	Paid to institution
	of study materials,		Click the tab key to add additional rows.
	medical writing, article processing charges, etc.)		
	No time limit for		
	this item.		
		Time frame: past 36 month	IS
2	Grants or contracts from	□ None	
	any entity (if not	NIH/NIA U01AG057195	Paid to institution
	indicated in item #1 above).	NIH/NINDS R21NS120629	Paid to institution
		Alzheimer's Association ZEN-21-848216, SG-21- 876655	Paid to institution
		Grant from American College of	Paid to institution
		Radiology/Alzheimer's Association, supported by	
		Eli Lilly/Life Molecular Imaging/GE Healthcare	
		Grant from Alliance for Therapeutics in	Paid to institution
		Neurodegeneration (supported by Genentech)	
	1	Rainwater Charitable Foundation	Paid to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	⊠ None	
4	Consulting fees	□ None	
		Eli Lilly GE Healthcare Roche Genentech	Paid to mePaid to mePaid to mePaid to me
5	Payment or honoraria for lectures,	None     Efficient LLC	Paid to me
	presentations,	Associate Editor – JAMA Neurology	Paid to me
	speakers	Miller Medical Communications	Paid to me
6	bureaus, manuscript writing or educational events Payment for	⊠ None	
	expert testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None     Johnson & Johnson	Paid to me
	Advisory Board		
10	Leadership or fiduciary role in other board,	⊠ None	

		ationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments we made to you or to your institution)	vere
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			

Date:	11/29/2023
Your Name:	Katherine L Possin
Manuscript Title:	Scalable plasma and digital cognitive markers for diagnosis and prognosis of ADRD
Manuscript Number (if known):	ADJ-D-23-01125

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH/NIA  NIH/NIA  NIH/NIA  NIH/NINDS  Global Brain Health Institute	P30AG062422 R35AG072362 U01NS128913		
		Global Brain Health Institute			
		Time frame: past 36 months	s		
c a ir	Grants or contracts from any entity (if not indicated in item #1 above).	None      French Foundation	Alzheimer's Association		
		Quest Diagnostics Rainwater Charitable Trust	Other grants from NIH not listed above		
3	Royalties or licenses	None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Strub Lecture (Ochsner Health)	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None     Alzheimer's Association	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<ul> <li>None</li> <li>Dementia Care Aware</li> <li>Alzheimer's Association Northern California</li> <li>IMPACT Advisory Board</li> </ul>	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				